A.F. KHALIRAKHMANOV, G.D. GATUYATULLINA, R.F. GAIFULLINA, A.A. RIZVANOV, E.I. MUKHAMETSHINA, B.M. SHARAFUTDINOV, S.V. ZINCHENKO

Kazan (Volga region) Federal University, Kazan

Khalirakhmanov A.F. ― PhD (medicine), doctor of the Department of X-ray and surgical methods of diagnostics and treatment, Senior Lecturer of the Department of Surgery, Obstetrics and Gynecology

Address: 18 Kremlevskaya Str., 420138, Kazan, Russian Federation, e-mail: ai.bolit@mail.ru

The new coronavirus, named SARS-CoV-2, has spread rapidly in the human population. Although the main manifestation of the disease is damage to the respiratory system, cardiovascular complications also often develop. Adverse cardiovascular complications such as myocarditis, acute myocardial infarction, and heart failure have been reported in patients with COVID-19. It should also be noted that patients with chronic cardiovascular diseases have a worse prognosis for the course and outcomes of the disease. Currently, there are no established methods for the diagnosis and treatment of cardiovascular lesions. This review considers some aspects of the pathophysiology, diagnosis, and treatment of cardiovascular disease in patients with COVID-19.

Key words: COVID-19, cardiovascular system, myocarditis, coronavirus.

(For citation:  Khalirakhmanov A.F., Gatuyatullina G.D., Gaifullina R.F., Rizvanov A.A., Mukhametshina E.I., Sharafutdinov B.M., Zinchenko S.V. Myocardial injury in patients with COVID 19. Practical Medicine. 2020. Vol. 18, № 1, P. 60-64)

REFERENCES

1. Lippi G., M Henry M.B. and Sanchis-Gomar F. Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19). European Journal of Preventive Cardiology. The European Society of Cardiology, 2020, 0(0), 1-3.
2. Hulot J.S. COVID-19 in patients with cardiovascular diseases. Arch Cardiovasc Dis, 2020, S1875-2136(20)30080-2.
3. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, 10.1038/s41569-020-0360-5
4. Chan J.F., Kok K.H., Zhu Z. et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 2020.
5. Tan W., Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol, 2020, S0167-5273(20)31593-X.
6. Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis [published online]. Prog Cardiovasc Dis [published online], 2020.
7. Kochi A.N., Tagliari A.P., Forleo G.B., Fassini G.M. and Tondo C. Cardiac and arrhythmic complications in Covid-19 patients. Journal of Cardiovascular Electrophysiology,
8. Liu Y., Yang Y., Zhang C. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci, 2020, no. 63 (3), pp. 364-374.
9. Bansal M. Cardiovascular Disease and COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020, vol. 14, pp. 247-250.

10. Kow C.S., Zaidi, S.T.R. and Hasan S.S. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. Am J Cardiovasc Drugs, 2020.
11. Huang X., Wei F., Hu L, Wen L., Chen K. Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med, 2020, no. 23 (4), pp. 268-271.
12. Chen C., Chen C., Yan J.T., Zhou N., Zhao J.P., Wang D.W. Analysis of Myocardial Injury in Patients With COVID-19 and Association Between Concomitant Cardiovascular Diseases and Severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi, 2020, no. 48 (0):E008.

13. Shi H., Han X., Jiang N. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 2020.
14. Rizzo P., Vieceli Dalla Sega F., Fortini F., Marracino L., Rapezzi C., Ferrari R. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Res Cardiol, 2020, no. 115 (3), 31.
15. Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. Journal of the American College of Cardiology.
16. Kapoor A., Pandurangi U., Arora V. et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society. Indian Pacing Electrophysiol J, 2020, S0972-6292(20)30038
17. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet Published Online, 2020.
18. Haeck G., Ancion A., Marechal P., Oury C., Lancellotti P. COVID-19 and cardiovascular diseases. Rev Med Liege, 2020, no. 75 (4), pp. 226–232.
19. Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular Considerations for Zhonghua Xin Xue Guan Bing Za Zhi. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19. Editorial Board of Chinese Journal of Cardiology, 2020.
20. Fried J.A., Ramasubbu K., Bhatt R. et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation, 2020. [published online].
21. Lee S.M., Takemoto S., Wallace A.W. Association between withholding angiotensin receptor blockers in the early postoperative period and 30-day mortality: a cohort study of the Veterans Affairs Healthcare System. Anesthesiology, 2015, no. 123 (2), pp. 288-306.
22. Vaduganathan, Vardeny O. et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. [published online], 2020.
23. Vuorio A., Watts G.F., Kovanen P.T. Familial hypercholesterolemia and COVID-19: triggering of increased sustained cardiovascular risk. J Intern Med,
24. Battistoni A., Volpe M. Might rennin-angiotensin system blockers play a role in the COVID-19 pandemic? European Heart Journal ― Cardiovascular Pharmacotherapy,
25. Guo T., Fan Y., Chen M. et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 2020.